2.22

1.33% -0.03

Lexicon Pharmaceuticals Inc (LXRX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché LXRX Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$2.25

Aprire:

$2.25

Volume 24 ore:

2.30M

Relative Volume:

0.73

Capitalizzazione di mercato:

$986.12M

Reddito:

$69.64M

Utile/perdita netta:

$-26.09M

Rapporto P/E:

-31.05

EPS:

-0.0715

Flusso di cassa netto:

$-38.80M

1 W Prestazione:

-4.31%

1M Prestazione:

+18.09%

6M Prestazione:

+89.74%

1 anno Prestazione:

+96.46%

Intervallo 1D:

$2.14

$2.25

Intervallo di 1 settimana:

$2.14

$2.435

Portata 52W:

$1.00

$2.68

Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile

Nome

Lexicon Pharmaceuticals Inc

Settore

Healthcare (1096)

Industria

Biotechnology (616)

Telefono

(281) 863-3000

Indirizzo

2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS

Dipendente

Cinguettio

@LexPharma

Prossima data di guadagno

2026-08-05

Ultimi documenti SEC

LXRX's Discussions on Twitter

Compare LXRX vs VRTX, REGN, ARGX, ALNY, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
LXRX Lexicon Pharmaceuticals Inc	2.22	986.12M	69.64M	-26.09M	-38.80M	-0.0715
VRTX Vertex Pharmaceuticals Inc	485.39	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	39.89B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	39.73B	742.00K	-1.37B	-1.07B	-7.0731

Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-03-05	Downgrade	Leerink Partners	Outperform → Market Perform
2024-06-17	Iniziato	H.C. Wainwright	Buy
2024-04-30	Iniziato	Leerink Partners	Outperform
2023-03-07	Iniziato	Jefferies	Hold
2022-08-12	Iniziato	Piper Sandler	Overweight
2021-01-29	Aggiornamento	JP Morgan	Underweight → Neutral
2021-01-29	Downgrade	Wedbush	Outperform → Neutral
2020-12-08	Aggiornamento	Citigroup	Neutral → Buy
2020-11-18	Aggiornamento	Gabelli & Co	Hold → Buy
2019-12-11	Downgrade	Gabelli & Co	Buy → Hold
2019-11-08	Downgrade	Citigroup	Buy → Neutral
2019-09-11	Aggiornamento	Gabelli & Co	Hold → Buy
2019-07-29	Downgrade	Stifel	Buy → Hold
2019-03-25	Aggiornamento	Gabelli & Co	Sell → Hold
2018-07-31	Reiterato	Stifel	Buy
2018-02-23	Downgrade	Needham	Buy → Hold
2018-02-14	Downgrade	JP Morgan	Neutral → Underweight
2017-03-01	Reiterato	H.C. Wainwright	Buy
2017-03-01	Reiterato	Wedbush	Outperform
2016-10-07	Iniziato	H.C. Wainwright	Buy
2016-08-05	Reiterato	Wedbush	Outperform
2016-08-02	Iniziato	Citigroup	Buy
2016-03-02	Reiterato	Wedbush	Outperform
2015-11-09	Reiterato	Wedbush	Outperform
2015-09-28	Aggiornamento	Gabelli & Co	Sell → Hold
2015-09-18	Downgrade	Gabelli & Co	Hold → Sell
2015-08-10	Downgrade	JP Morgan	Overweight → Neutral

Mostra tutto

Lexicon Pharmaceuticals Inc Borsa (LXRX) Ultime notizie

Jul 10, 2026

What Lexicon Pharmaceuticals (LXRX)'s Broad Russell Index Inclusion Means For Shareholders - simplywall.st

Jul 10, 2026

Jul 08, 2026

Lexicon Pharmaceuticals outlines its path in gastrointestinal disease. Drug pipeline and Nasdaq list - ad-hoc-news.de

Jul 08, 2026

Lexicon Pharmaceuticals (NASDAQ:LXRX) Scores Perfect 10 Technical Rating After 119% Rally - ChartMill

Jul 08, 2026

Jul 07, 2026

Lexicon Pharmaceuticals highlights diabetes drug focus. Strategy matters more than near-term headlin - ad-hoc-news.de

Jul 07, 2026

Jul 06, 2026

LXRX News | LEXICON PHARMACEUTICALS INC (NASDAQ:LXRX) - ChartMill

Jul 06, 2026

Jul 05, 2026

Earnings call transcript: Lexicon Pharmaceuticals Q1 2026 sees dramatic revenue surge - Investing.com

Jul 05, 2026

Jul 03, 2026

Lexicon Pharmaceuticals (LXRX) Gains on Russell 3000 Inclusion - Yahoo Finance

Jul 03, 2026

Jul 01, 2026

How Lexicon Pharma’s Expanded Russell Index Footprint Shapes Its Pipeline Narrative for Investors (LXRX) - simplywall.st

Jul 01, 2026

Jun 29, 2026

Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com

Jun 29, 2026

Lexicon Pharmaceuticals, Inc.(NasdaqCM: LXRX) added to Russell 2000 Index - marketscreener.com

Jun 29, 2026

Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell 2500 Growth Benchmark - marketscreener.com

Jun 29, 2026

Here's why you should add LXRX stock to your portfolio now - MSN

Jun 29, 2026

Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell 2000 Growth Benchmark - marketscreener.com

Jun 29, 2026

Lexicon Pharmaceuticals, Inc.(NasdaqCM: LXRX) added to Russell 3000E Index - marketscreener.com

Jun 29, 2026

Jun 28, 2026

Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell 3000E Growth Benchmark - marketscreener.com

Jun 28, 2026

Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell 3000 Growth Benchmark - marketscreener.com

Jun 28, 2026

LXRX Surges As Traders Pounce On Strong Breakout - StocksToTrade

Jun 28, 2026

LXRX Jumps As Traders Focus On Breakout Momentum - timothysykes.com

Jun 28, 2026

Jun 27, 2026

LXRX Stock Climbs As Bullish Momentum Attracts Short-Term Traders - StocksToTrade

Jun 27, 2026

LXRX Climbs As Bulls Press Multi-Day Breakout - timothysykes.com

Jun 27, 2026

Jun 26, 2026

Lexicon Pharmaceuticals stock hits 52-week high at $2.53 By Investing.com - Investing.com Nigeria

Jun 26, 2026

Lexicon Pharmaceuticals debuts HCM education booth at heart failure conference - Traders Union

Jun 23, 2026